CA2895131A1 - Medicament for atrophy treatment or increasing cell growth - Google Patents

Medicament for atrophy treatment or increasing cell growth Download PDF

Info

Publication number
CA2895131A1
CA2895131A1 CA2895131A CA2895131A CA2895131A1 CA 2895131 A1 CA2895131 A1 CA 2895131A1 CA 2895131 A CA2895131 A CA 2895131A CA 2895131 A CA2895131 A CA 2895131A CA 2895131 A1 CA2895131 A1 CA 2895131A1
Authority
CA
Canada
Prior art keywords
cells
serf2
cell
muscle
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2895131A
Other languages
English (en)
French (fr)
Inventor
Rudolf Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIMU TRADE CONSULTING & Co LEASING KG GmbH
Original Assignee
SIMU TRADE CONSULTING & Co LEASING KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIMU TRADE CONSULTING & Co LEASING KG GmbH filed Critical SIMU TRADE CONSULTING & Co LEASING KG GmbH
Publication of CA2895131A1 publication Critical patent/CA2895131A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2895131A 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth Abandoned CA2895131A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197192.3 2012-12-14
EP12197192.3A EP2742935A1 (en) 2012-12-14 2012-12-14 SERF2 for the treatment of atrophy and for increasing cell growth
PCT/EP2013/076547 WO2014090991A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Publications (1)

Publication Number Publication Date
CA2895131A1 true CA2895131A1 (en) 2014-06-19

Family

ID=47355920

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2895131A Abandoned CA2895131A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Country Status (7)

Country Link
US (2) US9637529B2 (enExample)
EP (2) EP2742935A1 (enExample)
JP (1) JP2016508123A (enExample)
CN (1) CN105163726A (enExample)
AU (1) AU2013357283A1 (enExample)
CA (1) CA2895131A1 (enExample)
WO (1) WO2014090991A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521009A (ja) 2008-05-23 2011-07-21 シワ コーポレイション 再生を促進させる方法、組成物及び装置
JP6976847B2 (ja) 2014-09-19 2021-12-08 シワ コーポレイション 炎症及び自己免疫障害を治療するための抗ａｇｅ抗体
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
DK3677598T3 (da) 2016-02-19 2022-05-30 Siwa Corp Fremgangsmåde og sammensætning til behandling af cancer, drab på metastatiske cancerceller og forebyggelse af cancermetastaser under anvendelse af antistof mod avancerede glykeringsslutprodukter (age)
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
CN110022884A (zh) * 2016-11-30 2019-07-16 白雁生物技术公司 含有线粒体的药物组合物
JP2020516648A (ja) 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN113337460A (zh) * 2021-06-10 2021-09-03 呼和浩特职业学院 一种绵羊骨骼肌卫星细胞的高效分离和纯化方法
CN118108828B (zh) * 2022-11-29 2025-10-28 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
CN117538545B (zh) * 2024-01-09 2024-07-05 上海众启生物科技有限公司 一种用于阿尔茨海默症检测的蛋白抗原组合及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
US20150307568A1 (en) 2015-10-29
EP2931264A1 (en) 2015-10-21
CN105163726A (zh) 2015-12-16
AU2013357283A1 (en) 2015-07-09
WO2014090991A1 (en) 2014-06-19
JP2016508123A (ja) 2016-03-17
US20170253641A1 (en) 2017-09-07
US9637529B2 (en) 2017-05-02
EP2742935A1 (en) 2014-06-18

Similar Documents

Publication Publication Date Title
US9637529B2 (en) Medicament for atrophy treatment or increasing cell growth
Wang et al. Slit3 secreted from M2-like macrophages increases sympathetic activity and thermogenesis in adipose tissue
Fernandez et al. Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype
Wu et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis
Schuger et al. Retinoic acid stimulates mouse lung development by a mechanism involving epithelial-mesenchymal interaction and regulation of epidermal growth factor receptors
US10563175B2 (en) Method for generating endothelial colony forming cell-like cells
Kim et al. DJ-1 promotes angiogenesis and osteogenesis by activating FGF receptor-1 signaling
KR20190102015A (ko) 생체 조직 손상의 수복제 및 그 수복제의 제조 방법
Hashimoto et al. Long-term activation of c-Fos and c-Jun in optic nerve head astrocytes in experimental ocular hypertension in monkeys and after exposure to elevated pressure in vitro
Xu et al. IL-18 promotes erythrophagocytosis and erythrocyte degradation by M1 macrophages in a calcific microenvironment
Cancedda et al. Ex-FABP: a fatty acid binding lipocalin developmentally regulated in chicken endochondral bone formation and myogenesis
Niu et al. Klotho enhances bone regenerative function of hPDLSCs via modulating immunoregulatory function and cell autophagy
US10357549B2 (en) Pigment epithelium-derived factor (PEDF) and peptide derivatives thereof for use in osteoblast differentiation and bone growth
KR101796826B1 (ko) Oct4 및 Sox2를 과발현하는 중간엽줄기세포 및 그 용도
JP2020509768A (ja) エネルギー代謝を調節するポリペプチド及びその使用
Ai et al. Retinal blood vessel‐origin yes‐associated protein (YAP) governs astrocytic maturation via leukaemia inhibitory factor (LIF)
AU2005313020A1 (en) Materials and methods related to Dickkopfs (DKK) and Neurogenesis
Kaiser et al. Brain stem slice conditioned medium contains endogenous BDNF and GDNF that affect neural crest boundary cap cells in co-culture
WO2004073731A1 (en) 14-3-3 protein for prevention and treatment of fibroproliferative disorders
JP2021521113A (ja) 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用
TWI902659B (zh) Ｐｅｄｆ衍生之短肽在肌腱癒合中的應用
Kim et al. APOA1 binding protein promotes lymphatic cell fate and lymphangiogenesis by relieving caveolae-mediated inhibition of VEGFR3 signaling
Li et al. Neurotrophine-3 may contribute to neuronal differentiation of mesenchymal stem cells through the activation of the bone morphogenetic protein pathway.
Niu IL10 signalling in human vascular development: human vascular cell differentiation from induced-pluripotent stem cells
Mody Effects of TGFβ2 and BMP4 Downstream Targets ID1 and ID3 in Trabecular Meshwork: Implications In Lowering IOP

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181213